car-t therapy versus autosct in dlbcl
Published 1 year ago • 125 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:06
car-t therapy vs autologous transplantation in r/r dlbcl
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
4:14
choosing the right car-t therapy for r/r dlbcl
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
3:05
car-t therapy in r/r dlbcl
-
3:42
an overview of car-t therapy in dlbcl and mcl
-
1:55
exploring first-line car-t therapy for the treatment of dlbcl
-
2:46
pros and cons of autologous and allogeneic car-ts
-
3:03
the future of car-t therapy for multiple myeloma
-
3:43
car t-cell toxicity: crs, icans and prolonged cytopenias
-
0:49
treating dlbcl with car-t: the best candidates and selecting a car-t product
-
2:25
selecting between autosct & car-t in dlbcl: patient selection, drug access, and long-term efficacy
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
0:58
the benefit of car-t therapy over autosct in 3l dlcbl & the promise of bispecifics in this setting
-
3:17
tcxpress™ vs car-t therapy & targeting leukemia with tcr t-cells
-
0:51
the value of car-t cell therapy in r/r dlbcl
-
1:46
real-world experiences with toxicity in patients treated with car-t cell therapy
-
3:19
how has car-t changed survival outcomes in dlbcl so far?
-
1:06
assessing metabolic tumor volume as a prognostic marker before car-t therapy for dlbcl
-
2:51
car t-cell therapy: crs and adverse effects
-
7:35
survey on the evaluation and management of dlbcl following suboptimal response to car-t therapy
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future